<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247337</url>
  </required_header>
  <id_info>
    <org_study_id>GI 1003</org_study_id>
    <nct_id>NCT01247337</nct_id>
  </id_info>
  <brief_title>Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma</brief_title>
  <official_title>Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Gemcitabine and Capecitabine in Combination With Cetuximab in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma. A Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dorte Nielsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in
      combination with systemic gemcitabine and capecitabine in combination with cetuximab in
      patient with non-resectable liver metastases from cholangiocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>6 months after last patient included</time_frame>
    <description>Time from treatment start to progression or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate.</measure>
    <time_frame>6 months after last patient included</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>6 months after last patient included</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>28 days after last treatment of last patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Single arm chemotherapy treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, capecitabine, gemcitabine, cetuximab</intervention_name>
    <description>Intrahepatic oxaliplatin</description>
    <arm_group_label>Single arm chemotherapy treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, capecitabine, gemcitabine cetuximab</intervention_name>
    <description>Oxaliplatin given intravenous</description>
    <arm_group_label>Single arm chemotherapy treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:• Informed consent

          -  Age &gt; 18 years

          -  Performance status 0-1; expected survival ≥ 3 months

          -  Patient with histologically or cytologically adenocarcinoma developed from cells in
             the gall bladder, extra- or intrahepatic bile ducts or malignant cells consistent with
             above mentioned and radiologic findings consistent with cholangiocarcinoma

          -  Liver metastases not suitable for surgery or other local treatment

          -  Extrahepatic disease should be excluded by PET-CT-scan.

          -  Prior treatment with chemotherapy or no progression on first line treatment

          -  Metastases &lt; 70 % of the liver

          -  neutrophile granulocytes ≥ 1.5 x 109/l og thrombocytes ≥ 100 x 109/l

          -  bilirubin &lt; 2.0 x UNL (upper normal limit).

          -  creatinine-clearance ≥ 30 ml/min.

          -  INR &lt; 2.

          -  Intrahepatic treatment can be accomplished

          -  The patients is approved by a multidisciplinary team

        Exclusion Criteria:• Other current or prior malignant disease except adequately treated and
        cured carcinoma in situ of the cervix or squamous cell carcinoma of the skin.

          -  Cytotoxic or experimental treatment within a 14 days period before start of trial
             medication

          -  The patient is not allowed to participate in other clinical trials.

          -  Any clinical symptoms suggesting peripheral neuropathy grade 2

          -  Other severe medical conditions

          -  Severe cardial disease or AMI &lt; 1 year

          -  Presence of diseases preventing oral therapy

          -  Patients with uncontrolled infection

          -  Pregnant or lactating women

          -  Women capable of childbearing not using a sufficient method of birth control

          -  Patients not able to understand the treatment or to collaborate

          -  Prior serious or unsuspected reaction after treatment with fluoropyrimidine

          -  Known prior hypersensitivity reactions to the agents

          -  Interstitial pneumonitis or pulmonary fibrosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magnus Bergenfeldt, Consultan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department og Gastroenterology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <last_update_submitted>March 20, 2014</last_update_submitted>
  <last_update_submitted_qc>March 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Dorte Nielsen</investigator_full_name>
    <investigator_title>Responsible Party was entered in the old format as Dorte Nielsen, professor DMSci, Department of Oncology, Herlev Hospital.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

